SUN PHARMACEUTICAL INDUSTRIES LIMITED

🇮🇳India

Country: 🇮🇳India

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis

Phase 2

Active, not recruiting

Conditions: Moderate to Severe Plaque Psoriasis

Interventions: Drug: SCD-044_Dose 3
Drug: Placebo
Drug: SCD-044_Dose 1
Drug: SCD-044_Dose 2

First Posted Date: 2020-09-28

Last Posted Date: 2024-10-22

Lead Sponsor: Sun Pharmaceutical Industries Limited

Target Recruit Count: 263

Registration Number: NCT04566666

Locations: 🇺🇸
Site # 21, Yuma, Arizona, United States
🇺🇸
Site # 12, Encino, California, United States
🇺🇸
Site # 13, Los Angeles, California, United States

and more 20 locations

Efficacy and Safety of MM-II for Treatment of Knee Pain in Subjects With Symptomatic Knee Osteoarthritis

Phase 2

Completed

Conditions: Osteoarthritis of Knee

Interventions: Drug: MM-II dose I
Drug: MM-II dose II
Drug: MM-II dose III
Drug: Placebo

First Posted Date: 2020-08-10

Last Posted Date: 2024-08-29

Lead Sponsor: Sun Pharmaceutical Industries Limited

Target Recruit Count: 397

Registration Number: NCT04506463

Locations: 🇺🇸
Sunpharma site no. 25, Riverside, California, United States
🇺🇸
Sunpharma site no. 22, Miami, Florida, United States
🇺🇸
Sunpharma site no. 12, Miami, Florida, United States

and more 22 locations

Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo

Phase 2

Completed

Conditions: Non-segmental Vitiligo

Interventions: Drug: AS012
Drug: Placebo

First Posted Date: 2020-07-27

Last Posted Date: 2023-03-27

Lead Sponsor: Sun Pharmaceutical Industries Limited

Target Recruit Count: 327

Registration Number: NCT04487860

Locations: 🇺🇸
Sun Pharma Site 04, Miami, Florida, United States
🇺🇸
Sun Pharma Site 15, Phoenix, Arizona, United States
🇺🇸
Sun Pharma Site 11, Mill Creek, Washington, United States

and more 25 locations

Effect of Cequa™ in Subjects With Dry Eye Disease

Phase 4

Completed

Conditions: Dry Eye Disease

Interventions: Drug: CequaTM (Cyclosporine 0.09%) ophthalmic solution

First Posted Date: 2020-04-22

Last Posted Date: 2024-02-06

Lead Sponsor: Sun Pharmaceutical Industries Limited

Target Recruit Count: 135

Registration Number: NCT04357795

Locations: 🇺🇸
Kannarr Eye Care, 2521 N Broadway, Pittsburg, Kansas, United States
🇺🇸
Eye Associates of Fort Myers, 4225 Evans Ave., Fort Myers, Florida, United States
🇺🇸
Bowden Eye and Associates, 7205 Bonneval Road, Jacksonville, Florida, United States

and more 2 locations

Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)

Phase 3

Active, not recruiting

Conditions: Active Psoriatic Arthritis

Interventions: Drug: matching placebo injections
Drug: TILD

First Posted Date: 2020-03-19

Last Posted Date: 2024-10-01

Lead Sponsor: Sun Pharmaceutical Industries Limited

Target Recruit Count: 292

Registration Number: NCT04314531

Locations: 🇺🇸
Sunpharma site no. 12, Covina, California, United States
🇺🇸
Sunpharma site no. 04, Miami Beach, Florida, United States
🇺🇸
Sunpharma site no. 02, New Port Richey, Florida, United States

and more 51 locations

Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)

Phase 3

Recruiting

Conditions: Active Psoriatic Arthritis

Interventions: Drug: TILD
Drug: matching placebo injections

First Posted Date: 2020-03-19

Last Posted Date: 2024-07-10

Lead Sponsor: Sun Pharmaceutical Industries Limited

Target Recruit Count: 472

Registration Number: NCT04314544

Locations: 🇪🇸
SunPharma Site No 23, Córdoba, Spain
🇪🇸
Sunpharma Site no. 118, Gran Canaria, Spain
🇪🇸
Sunpharma Site no 58, La Coruña, Spain

and more 136 locations

Post-authorization Safety Study on the Long Term Safety of Sonidegib in Patients With Locally Advanced Cell Carcinoma

Active, not recruiting

Conditions: Basal Cell Carcinoma

Interventions: Drug: sonidegib

First Posted Date: 2019-08-26

Last Posted Date: 2024-10-15

Lead Sponsor: Sun Pharmaceutical Industries Limited

Target Recruit Count: 323

Registration Number: NCT04066504

Locations: 🇮🇹
ASST Spedali Civili di Brescia, Brescia, Italy
🇩🇪
Universitaets-Hautklinik Kiel, Kiel, Germany
🇩🇪
Klinikum rechts der Isar, München, Germany

and more 44 locations

A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis

Phase 2

Active, not recruiting

Conditions: Moderate-to-severe Chronic Plaque Psoriasis

Interventions: Drug: Tildrakizumab
Drug: Placebo
Drug: Etanercept

First Posted Date: 2019-06-25

Last Posted Date: 2024-06-21

Lead Sponsor: Sun Pharmaceutical Industries Limited

Target Recruit Count: 130

Registration Number: NCT03997786

Locations: 🇺🇸
Site 2, Thousand Oaks, California, United States
🇺🇸
Site 1, Fountain Valley, California, United States
🇺🇸
Site 20, Miami, Florida, United States

and more 30 locations

Safety Study for Prospective Assessment of Pregnancy Outcomes in Patients Treated With Tildrakizumab

Recruiting

Conditions: Pregnancy Related

Interventions: Drug: Pregnant women exposed to tildrakizumab
Drug: Pregnant women not exposed to tildrakizumab

First Posted Date: 2019-06-20

Last Posted Date: 2024-11-08

Lead Sponsor: Sun Pharmaceutical Industries Limited

Target Recruit Count: 200

Registration Number: NCT03992729

Locations: 🇺🇸
Christina Chambers, San Diego, California, United States

A Comparative Study of SPARC's SDP-133 Once Daily and Lumigan in Subjects With Open Angle Glaucoma or Ocular Hypertension

Phase 3

Withdrawn

Conditions: Open Angle Glaucoma
Ocular Hypertension

Interventions: Drug: SDP-133
Drug: Lumigan

First Posted Date: 2019-04-25

Last Posted Date: 2021-11-19

Lead Sponsor: Sun Pharmaceutical Industries Limited

Registration Number: NCT03927443

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy